After inking a string of pipeline deals, Boehringer Ingelheim is doing a makeover of the top executive team

After a string of pipeline deals aimed at revitalizing the R&D group, the decidedly private German company is undergoing a high-level makeover of the top team.

Boehringer reported Monday that their pharma and biopharma business chief Allan Hillgrove has stepped down from their board of managing directors and will soon retire from the company after a 37-year stint that started with his position as a sales rep.